Patients With IBD Treated With Infliximab Who Are Vaccinated Against SARS-CoV-2 More Likely To Have Breakthrough Infection Than Patients Treated With Vedolizumab, Researchers Say

HCPlive (12/7, Walter) reports, “Patients with inflammatory bowel disease (IBD) treated with infliximab who were vaccinated against SARS-CoV-2 were more likely to have a breakthrough infection than patients treated with vedolizumab, but the benefits of th...